Not so safe haven for Novartis

Novartis second quarter results showed pleasing growth, but the Swiss-based pharmaceuticals company is struggling to deal with the appreciation of the Swiss franc. Lex's John Authers and Luke Templeman discuss how Novartis and other Swiss multi-national companies might hedge against such macro-economic shocks.